Reliance Life Sciences Added to Import Alert 66-40: The CGMP…

Regulatory Event

What FDA has not published alongside the listing is a specific deficiency narrative. IA 66-40 entries do not always carry one, and this is such a case: the Red List cites the standard “not operating in conformity with CGMP requirements” language across every one of the eleven product-code rows, without breaking out a distinct finding for any single line. No Form 483, no inspection classification, and no companion Warning Letter for Reliance Life Sciences was located in FDA’s public Warning Letter database or in general web search as of this writing. That gap matters more here than it would for a narrower listing: when a DWPE action covers biologics and biosimilars alongside conventional drug products, the underlying CGMP failure could plausibly sit anywhere from a documentation control weakness to a data integrity or aseptic processing finding, and until the inspection record becomes public, quality teams evaluating exposure are working from FDA’s conclusion without FDA’s evidence.

DWPE is not a warning; it is an operational barrier. Under Section 801 of the Federal Food, Drug, and Cosmetic Act and 21 CFR § 1.94, FDA may detain a shipment without physical examination once the exporting firm appears on the IA 66-40 Red List, and the burden falls to the owner, consignee, or other responsible party to provide documentation showing the CGMP violation has been adequately corrected before release will be considered. In practice, every US customer sourcing biosimilars, plasma proteins, Active Pharmaceutical Ingredients (APIs), or finished dosage forms from this facility now faces halted supply unless the importer of record initiates a Compliance Monitoring Program (CMP): a validated sampling plan, testing through an FDA-qualified laboratory, and batch-by-batch release submissions to the responsible FDA district office, sustained until FDA is willing to schedule a reinspection.

What the Record Documents

Prior IA 66-40 cases involving blanket, facility-wide listings offer a useful — if imperfect — reference point for scale and timeline. Ranbaxy’s Paonta Sahib and Dewas facilities were listed for data integrity failures under 21 CFR § 211.194(a), with more than 30 marketed products affected and four-plus years of batch-by-batch CMP testing before reinspection; Sun Pharmaceutical’s Halol facility was listed in December 2014 following a Warning Letter citing data integrity and sterility assurance failures, disrupting roughly 150 products, with removal in March 2017 after 18 months of CMP performance and two consecutive satisfactory reinspections. None of those precedents involved a biosimilar or biologics manufacturer at this scale — Reliance Life Sciences appears to be a novel case among recent IA 66-40 actions in that respect — which means the CMP pathway here will likely need to address process areas without a close public precedent: cell culture and fermentation process consistency, potency and comparability assay validation, and aseptic fill-finish controls, in addition to the conventional CGMP documentation and laboratory-control areas that general non-conformance findings typically touch.

Technical and Quality Context

For Reliance Life Sciences, a credible remediation pathway starts with the same discipline any facility-wide listing demands: engaging the FDA district office responsible for the action, obtaining the underlying inspection findings if a Form 483 or equivalent record exists, and scoping a Corrective and Preventive Action (CAPA) program to the actual CGMP gap FDA identified rather than to the general language on the Red List. Given the blanket nature of the listing across biologics, biosimilars, and conventional drug product lines, a credible corrective action plan will likely need to demonstrate quality system integrity across multiple manufacturing platforms simultaneously — batch record review under 21 CFR § 211.192, laboratory record integrity and attributability under § 211.194(a), and, for the biologics-adjacent lines, process validation evidence consistent with the CMC expectations FDA applies to biosimilar manufacturing.

US companies sourcing biosimilars, plasma-derived proteins, APIs, or finished products from this facility should treat this listing as an immediate supplier qualification trigger, independent of whether the underlying deficiency detail ever becomes public. That means auditing current and pipeline product agreements against this specific facility, confirming with distributors or licensing partners whether Reliance-manufactured material sits further upstream in a supply or licensing chain, and opening an alternative-sourcing or dual-sourcing assessment in parallel with monitoring FDA’s Warning Letter postings for the underlying finding. For biosimilar sponsors in particular, a DWPE listing at a manufacturing partner is not a problem that resolves on its own timeline — regulatory and commercial teams need to understand the CMP trajectory now, not after a launch or supply commitment is already at risk.

Decision Relevance

XGene Consulting supports companies at both ends of this exposure: sponsors and importers assessing whether a listed manufacturing partner’s CGMP gaps create downstream regulatory or supply liability, and manufacturers like Reliance Life Sciences building the CMP documentation package, root cause assessment, and reinspection readiness plan FDA expects before considering removal from Import Alert 66-40 — including the biologics-specific process validation evidence a listing of this scope will likely require. If you manage a supplier or licensing relationship tied to a site on Import Alert 66-40, or you are the site working to get off it, connect with me on LinkedIn or through xgeneconsulting.com — the earlier a disciplined CMP strategy starts, the shorter the DWPE period tends to run.